Here, the authors summarize current knowledge regarding mechanisms of remyelination and remyelination failure in multiple sclerosis and animal models of the disease and discuss strategies to overcome the translational roadblock in the field of remyelination-promoting therapies.

Results from a phase III trial have set zavegepant as the first intranasal gepant to be approved by the FDA for the acute treatment of migraine. The therapeutic benefits were modest, however, and more work is needed to address unmet treatment needs.

Bruton tyrosine kinase inhibitors are an emerging treatment for multiple sclerosis. Krämer et al. consider the evidence that central nervous system-penetrant Bruton tyrosine kinase inhibitors might target both peripheral immune cells and compartmentalized inflammation and discuss promising preliminary results of clinical trials of these agents in multiple sclerosis.

An approach that uses magnetic nanotubes and a rotating magnetic field to induce cell death shows promise in a mouse model of glioblastoma.

Researchers in China have developed a functional nucleic acid-based responsive artificial enzyme that enables continuous production of levodopa in a mouse model of Parkinson disease.

A new study indicates loss of hypothalamic melanin-concentrating hormone in ALS, providing insights into the mechanisms underlying weight loss in individuals with the disease.